A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy
Recruiting in Palo Alto (17 mi)
+19 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: AstraZeneca
Prior Safety Data
Trial Summary
What is the purpose of this trial?
A study to investigate the analgesic efficacy of AZD2423 compared with placebo after 28 days treatment in patients with painful diabetic polyneuropathy.
Research Team
BJ
Bror Jonzon
Principal Investigator
AstraZeneca R&D Södertälje
Eligibility Criteria
Inclusion Criteria
Provision of signed informed consent form
Males and female of non-child bearing potential patients aged 18 to 80 years
Patients with neuropathic pain due to painful diabetic polyneuropathy.
Treatment Details
Interventions
- AZD2423 (Other)
- Placebo (Other)
Participant Groups
3Treatment groups
Experimental Treatment
Placebo Group
Group I: AZD2423, 20 mgExperimental Treatment1 Intervention
Tablets, 20 mg once daily in the morning.
Group II: AZD2423, 150 mgExperimental Treatment1 Intervention
Tablets, 150 mg once daily in the morning.
Group III: PlaceboPlacebo Group1 Intervention
Tablets, placebo, once daily in the morning.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Research SitePhoenix, AZ
Research SiteLos Angeles, CA
Research SiteMiami, FL
Research SiteEtobicoke, Canada
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Trials
4491
Patients Recruited
290,540,000+